List of antiviral drugs: Difference between revisions
Appearance
Content deleted Content added
No edit summary |
WikiKopfkino (talk | contribs) m Copyedit (minor) - Duplicate words |
||
(25 intermediate revisions by 17 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description| |
{{Short description|This is a list of antiviral drugs.}} |
||
Antiviral drugs are different from antibiotics. Flu antiviral drugs are different from antiviral drugs used to treat other infectious diseases such as COVID-19. Antiviral drugs prescribed to treat COVID-19 are not approved or authorized to treat flu.<ref>{{cite web | url=https://www.cdc.gov/flu/treatment/whatyoushould.htm | title=What You Should Know about Flu Antiviral Drugs | date=15 December 2022 }}</ref> |
|||
{{Multiple issues| |
{{Multiple issues| |
||
{{Update|date=August 2020}} |
{{Update|date=August 2020}} |
||
{{More |
{{More citations needed|date=August 2020}} |
||
}} |
}} |
||
{| class="wikitable sortable" |
{| class="wikitable sortable" |
||
Line 12: | Line 13: | ||
!Component |
!Component |
||
!Type |
!Type |
||
!Year |
!Year approved |
||
|- |
|- |
||
|[[Abacavir]] |
|[[Abacavir]] |
||
|[[HIV]] |
|[[HIV]] |
||
|[[ViiV Healthcare]] |
|||
| |
|||
| |
| |
||
|[[Nucleoside analogue]] [[reverse transcriptase inhibitor]] (NRTI) |
|[[Nucleoside analogue]] [[reverse transcriptase inhibitor]] (NRTI) |
||
|1998 |
|||
| |
|||
|- |
|- |
||
|[[Acyclovir]] (Aciclovir) |
|[[Acyclovir]] (Aciclovir) |
||
|[[Herpes Simplex]], |
|[[Herpes Simplex]], [[chickenpox]],<ref>{{cite web|title=Acyclovir|url=https://www.drugs.com/monograph/acyclovir.html|publisher=The American Society of Health-System Pharmacists|access-date=Jan 1, 2015|url-status=live|archive-url=https://web.archive.org/web/20150105113809/http://www.drugs.com/monograph/acyclovir.html|archive-date=2015-01-05}}</ref> [[varicella zoster virus]] |
||
| |
| |
||
| |
| |
||
|[[guanosine]] analogue RTI |
|||
|NRTI |
|||
|1981 |
|||
| |
|||
|- |
|- |
||
|[[Adefovir]] |
|[[Adefovir]] |
||
|[[Hepatitis B]]<ref name="pmid12606735">{{cite journal | vauthors = Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL | display-authors = 6 | title = Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | journal = The New England Journal of Medicine | volume = 348 | issue = 9 | pages = 808–16 | date = February 2003 | pmid = 12606735 | doi = 10.1056/NEJMoa020681 | url = https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1053&context=intmed_pubs }}</ref> |
|[[Hepatitis B]]<ref name="pmid12606735">{{cite journal | vauthors = Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL | display-authors = 6 | title = Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B | journal = The New England Journal of Medicine | volume = 348 | issue = 9 | pages = 808–16 | date = February 2003 | pmid = 12606735 | doi = 10.1056/NEJMoa020681 | url = https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=1053&context=intmed_pubs | doi-access = free }}</ref> |
||
|Gilead Sciences |
|Gilead Sciences |
||
| |
| |
||
|RTI |
|RTI |
||
|2002 ([[FDA]]), 2003 ([[European Union|EU]]) |
|||
| |
|||
|- |
|- |
||
|[[Amantadine]] |
|[[Amantadine]] |
||
Line 46: | Line 47: | ||
| |
| |
||
| |
| |
||
|[[ |
|[[Immunomodulatory]] [[double-stranded RNA]] |
||
| |
| |
||
|- |
|- |
||
Line 53: | Line 54: | ||
| |
| |
||
| |
| |
||
|[[Protease inhibitor (pharmacology)|Protease inhibitor]] |
|[[Protease inhibitor (pharmacology)|Protease inhibitor]] (PI) |
||
| |
| |
||
|- |
|- |
||
Line 67: | Line 68: | ||
| |
| |
||
| |
| |
||
|PI |
|||
|Protease inhibitor |
|||
| |
| |
||
|- |
|- |
||
Line 75: | Line 76: | ||
| |
| |
||
| |
| |
||
* Efavirenz: NNRTI |
* Efavirenz: Non-nucleoside RTI (NNRTI) |
||
* Emtricitabine: NRTI |
* Emtricitabine: NRTI |
||
* Tenofovir disoproxil: NRTI |
* Tenofovir disoproxil: NRTI |
||
Line 102: | Line 103: | ||
| |
| |
||
|Protease inhibitor |
|Protease inhibitor |
||
| |
|||
|FDA approved 2011, withdrawn from market January 2015 |
|||
* FDA approved 2011 |
|||
* Withdrawn 2015 |
|||
|- |
|- |
||
|[[Bulevirtide]] |
|[[Bulevirtide]] |
||
|[[Hepatitis D]] |
|[[Hepatitis D]]/[[Hepatitis B|B]] |
||
| |
| |
||
| |
| |
||
|[[ |
|[[Sodium/bile acid cotransporter]] inactivator |
||
| |
| |
||
|- |
|- |
||
Line 138: | Line 141: | ||
| |
| |
||
| |
| |
||
|[[NS5A]] |
|[[NS5A]] inhibitor |
||
| |
| |
||
|- |
|- |
||
Line 145: | Line 148: | ||
| |
| |
||
|antiretroviral |
|antiretroviral |
||
|HIV |
|HIV PI |
||
| |
| |
||
|- |
|- |
||
Line 182: | Line 185: | ||
| |
| |
||
| |
| |
||
|[[ |
|[[Integrase inhibitor]] |
||
| |
| |
||
|- |
|- |
||
Line 193: | Line 196: | ||
|- |
|- |
||
|[[Edoxudine]] |
|[[Edoxudine]] |
||
| |
|Herpes Simplex |
||
| |
| |
||
| |
| |
||
|[[Thymidine |
|[[Thymidine]] analogue inhibitor |
||
| |
| |
||
|- |
|- |
||
|[[Efavirenz]] |
|[[Efavirenz]] |
||
|HIV |
|HIV |
||
|Mylan |
|[[Mylan]] |
||
| |
| |
||
|NNRTI |
|NNRTI |
||
|1998 |
|||
| |
|||
|- |
|- |
||
|[[Elvitegravir]] |
|[[Elvitegravir]] |
||
|HIV |
|HIV |
||
|Gilead Sciences |
|||
| |
| |
||
|Integrase inhibitor |
|||
| |
| |
||
* 2012 ([[Combination drug|Fixed-dose combo]] [[Stribild]]) |
|||
|integrase inhibitor |
|||
* 2014 (single pill) |
|||
| |
|||
* 2015 ([[Genvoya]]) |
|||
|- |
|- |
||
|[[Emtricitabine]] |
|[[Emtricitabine]] |
||
|HIV |
|HIV |
||
|Gilead Sciences |
|||
| |
|||
| |
| |
||
|NRTI |
|NRTI |
||
|2003 |
|||
| |
|||
|- |
|- |
||
|[[Enfuvirtide]] |
|[[Enfuvirtide]] |
||
Line 225: | Line 231: | ||
| |
| |
||
|Entry inhibitor |
|Entry inhibitor |
||
|2003 |
|||
| |
|||
|- |
|- |
||
|[[Ensitrelvir]] |
|[[Ensitrelvir]] |
||
Line 239: | Line 245: | ||
| |
| |
||
|NRTI |
|NRTI |
||
|2005 |
|||
| |
|||
|- |
|- |
||
|[[Etravirine]] (Intelence)<ref>{{cite web | title=Intelence- etravirine tablet | website=DailyMed | date=9 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a9cbc29-9f15-4b24-8d86-206b82887f3d | access-date=21 September 2020}}</ref> |
|[[Etravirine]] (Intelence)<ref>{{cite web | title=Intelence- etravirine tablet | website=DailyMed | date=9 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a9cbc29-9f15-4b24-8d86-206b82887f3d | access-date=21 September 2020}}</ref> |
||
Line 246: | Line 252: | ||
| |
| |
||
|NNRTI |
|NNRTI |
||
|2008 |
|||
| |
|||
|- |
|- |
||
|[[Famciclovir]] |
|[[Famciclovir]] |
||
Line 252: | Line 258: | ||
| |
| |
||
| |
| |
||
|[[ |
|[[Guanosine]] analogue |
||
|1994 |
|||
| |
|||
|- |
|- |
||
|[[Fomivirsen]] |
|[[Fomivirsen]] |
||
|AIDS |
|AIDS |
||
| |
| |
||
|[[Anti-sense]] [[oligonucleotide]] |
|||
|Anti-sense |
|||
| |
| |
||
* FDA-licensed in 1998 |
|||
| |
|||
* Withdrawn in EU (2002), US (2006) |
|||
| |
|||
|- |
|- |
||
|[[Fosamprenavir]] |
|[[Fosamprenavir]] |
||
|HIV |
|HIV |
||
|[[ViiV Healthcare]] |
|||
| |
| |
||
|Amprenavir [[pro-drug]] |
|||
| |
|||
|2003 (FDA), 2004 ([[European Medicines Agency|EMA]]) |
|||
| |
|||
| |
|||
|- |
|- |
||
|[[Foscarnet]] |
|[[Foscarnet]] |
||
Line 273: | Line 281: | ||
| |
| |
||
| |
| |
||
|[[ |
|[[Pyrophosphate]] [[Structural analog|analogue]] [[DNA polymerase inhibitor]] |
||
|1991 |
|||
| |
|||
|- |
|- |
||
|[[Ganciclovir]] (Cytovene)<ref>{{cite web | title=Cytovene IV- ganciclovir sodium injection, powder, lyophilized, for solution | website=DailyMed | date=19 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0318acb-96ab-4750-8e6b-91c4bfc6487b | access-date=21 September 2020}}</ref> |
|[[Ganciclovir]] (Cytovene)<ref>{{cite web | title=Cytovene IV- ganciclovir sodium injection, powder, lyophilized, for solution | website=DailyMed | date=19 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0318acb-96ab-4750-8e6b-91c4bfc6487b | access-date=21 September 2020}}</ref> |
||
Line 280: | Line 288: | ||
| |
| |
||
| |
| |
||
| |
|Competitive nucleoside analogue [[deoxyguanosine triphosphate|dGTP]] inhibitor |
||
|1988 |
|||
| |
|||
|- |
|- |
||
|[[Ibacitabine]] |
|[[Ibacitabine]] |
||
Line 294: | Line 302: | ||
| |
| |
||
| |
| |
||
|Entry inhibitor |
|||
| |
|||
|2018 |
|||
| |
|||
|- |
|- |
||
|[[Idoxuridine]] |
|[[Idoxuridine]] |
||
Line 301: | Line 309: | ||
| |
| |
||
| |
| |
||
|[[deoxyuridine|dU]] analogue inhibitor |
|||
| |
|||
|1962 |
|||
| |
|||
|- |
|- |
||
|[[Imiquimod]] |
|[[Imiquimod]] |
||
Line 308: | Line 316: | ||
| |
| |
||
| |
| |
||
| |
|Opioid growth factor receptor (OGFr) agonist |
||
|1997 |
|||
| |
|||
|- |
|- |
||
|[[ |
|[[Inosine pranobex]] |
||
|Herpes Simplex |
|Herpes Simplex |
||
| |
| |
||
| |
| |
||
|[[thymus|Thymus hormone]] [[immunostimulant]] |
|||
| |
|||
| |
| |
||
|- |
|- |
||
Line 322: | Line 330: | ||
| |
| |
||
| |
| |
||
| |
|PI |
||
|1996 |
|||
| |
|||
|- |
|- |
||
|[[Lamivudine]] |
|[[Lamivudine]] |
||
Line 329: | Line 337: | ||
| |
| |
||
| |
| |
||
|[[cytidine]] analogue |
|[[cytidine]] analogue RTI |
||
| |
| |
||
|- |
|- |
||
Line 365: | Line 373: | ||
| |
| |
||
| |
| |
||
| |
|||
|- |
|||
|[[Molnupiravir]] |
|||
|[[COVID-19]] |
|||
| |
|||
| |
|||
|viral [[RNA polymerase]] inhibitor |
|||
| |
| |
||
|- |
|- |
||
Line 381: | Line 396: | ||
| |
| |
||
|- |
|- |
||
|[[Nirmatrelvir/ritonavir]] (Paxlovid) |
|||
|[[Nevirapine]] |
|||
|[[COVID-19]] |
|||
|HIV |
|||
|[[Pfizer]] |
|||
| |
| |
||
|[[3C-like protease]] [[Enzyme inhibitor|inhibitor]] (Nirmatrelvir) / inhibition of [[metabolism]] of nirmatrelvir (ritonavir) |
|||
| |
|||
|non-[[nucleoside]] [[reverse transcriptase inhibitor]] |
|||
| |
| |
||
|- |
|- |
||
|[[Nevirapine]] |
|||
|[[Nexavir]] formerly (Kutapressin) |
|||
|HIV |
|||
|[[Herpes Zoster]] |
|||
| |
| |
||
| |
| |
||
|non-[[nucleoside]] [[reverse transcriptase inhibitor]] |
|||
|Liver derivative complex |
|||
| |
| |
||
|- |
|- |
||
Line 410: | Line 425: | ||
|- |
|- |
||
|[[Oseltamivir]] (Tamiflu)<ref>{{cite web | title=Tamiflu- oseltamivir phosphate capsule TAMIFLU- oseltamivir phosphate powder, for suspension | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee3c9555-60f2-4f82-a760-11983c86e97b | access-date=21 September 2020}}</ref> |
|[[Oseltamivir]] (Tamiflu)<ref>{{cite web | title=Tamiflu- oseltamivir phosphate capsule TAMIFLU- oseltamivir phosphate powder, for suspension | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee3c9555-60f2-4f82-a760-11983c86e97b | access-date=21 September 2020}}</ref> |
||
| |
|Influenza |
||
| |
| |
||
| |
| |
||
Line 416: | Line 431: | ||
| |
| |
||
|- |
|- |
||
|[[Peramivir]] (Rapivab)<ref>{{cite web | title=Rapivab- peramivir solution | website=DailyMed | date=3 August 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe04f6cd-e71c-4bd4-abac-97720bba2a0d | access-date=21 September 2020}}</ref> |
|||
|[[Penciclovir]] |
|||
|Influenza |
|||
|[[Herpes]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Peramivir]] |
|||
|[[Influenza]] |
|||
| |
| |
||
| |
| |
||
Line 432: | Line 440: | ||
|[[Penciclovir]] |
|[[Penciclovir]] |
||
|[[Herpes]] |
|[[Herpes]] |
||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Peramivir]] (Rapivab)<ref>{{cite web | title=Rapivab- peramivir solution | website=DailyMed | date=3 August 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe04f6cd-e71c-4bd4-abac-97720bba2a0d | access-date=21 September 2020}}</ref> |
|||
|[[Influenza]] |
|||
| |
| |
||
| |
| |
||
Line 480: | Line 481: | ||
|- |
|- |
||
|[[Rilpivirine]] (Edurant)<ref>{{cite web | title=Edurant- rilpivirine hydrochloride tablet, film coated | website=DailyMed | date=8 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03880372-2c68-45c6-a53a-f420c49541d6 | access-date=21 September 2020}}</ref> |
|[[Rilpivirine]] (Edurant)<ref>{{cite web | title=Edurant- rilpivirine hydrochloride tablet, film coated | website=DailyMed | date=8 June 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03880372-2c68-45c6-a53a-f420c49541d6 | access-date=21 September 2020}}</ref> |
||
|HIV |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Rilpivirine]] |
|||
|HIV |
|HIV |
||
| |
| |
||
Line 606: | Line 600: | ||
|- |
|- |
||
|[[Umifenovir]] |
|[[Umifenovir]] |
||
| |
|Influenza |
||
| |
| |
||
| |
| |
||
Line 613: | Line 607: | ||
|- |
|- |
||
|[[Valaciclovir]] (Valtrex)<ref>{{cite web | title=Valtrex- valacyclovir hydrochloride tablet, film coated | website=DailyMed | date=10 December 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8e0d8f8-cb73-4206-a484-88f5c4fbd719 | access-date=21 September 2020}}</ref> |
|[[Valaciclovir]] (Valtrex)<ref>{{cite web | title=Valtrex- valacyclovir hydrochloride tablet, film coated | website=DailyMed | date=10 December 2019 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f8e0d8f8-cb73-4206-a484-88f5c4fbd719 | access-date=21 September 2020}}</ref> |
||
| |
|Herpes Simplex/Zoster |
||
| |
| |
||
| |
| |
||
Line 619: | Line 613: | ||
| |
| |
||
|- |
|- |
||
|[[Valganciclovir]] (Valcyte)<ref>{{cite web | title=Valcyte- valganciclovir tablet, film coated VALCYTE- valganciclovir hydrochloride powder, for solution | website=DailyMed | date=9 August 2018 | url=https:// |
|[[Valganciclovir]] (Valcyte)<ref>{{cite web | title=Valcyte- valganciclovir tablet, film coated VALCYTE- valganciclovir hydrochloride powder, for solution | website=DailyMed | date=9 August 2018 | url=https://www.uptodate.com/contents/valganciclovir-drug-information?source=auto_suggest&selectedTitle=1~1---1~4---valganci&search=valganciclovir | access-date=3 September 2022}}</ref> |
||
|[[Cytomegalovirus]] (CMV) |
|||
|HIV |
|||
| |
| |
||
| |
| |
||
Line 661: | Line 655: | ||
| |
| |
||
|} |
|} |
||
==References== |
==References== |
Latest revision as of 14:31, 4 May 2024
Antiviral drugs are different from antibiotics. Flu antiviral drugs are different from antiviral drugs used to treat other infectious diseases such as COVID-19. Antiviral drugs prescribed to treat COVID-19 are not approved or authorized to treat flu.[1]
![]() | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
References
[edit]- ^ "What You Should Know about Flu Antiviral Drugs". 15 December 2022.
- ^ "Acyclovir". The American Society of Health-System Pharmacists. Archived from the original on 2015-01-05. Retrieved Jan 1, 2015.
- ^ Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. (February 2003). "Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B". The New England Journal of Medicine. 348 (9): 808–16. doi:10.1056/NEJMoa020681. PMID 12606735.
- ^ "Xofluza- baloxavir marboxil tablet, film coated". DailyMed. 28 October 2019. Retrieved 21 September 2020.
- ^ Degertekin B, Lok AS (May 2008). "Update on viral hepatitis: 2007". Curr. Opin. Gastroenterol. 24 (3): 306–11. doi:10.1097/MOG.0b013e3282f70285. PMID 18408458. S2CID 43762307
- ^ "Tybost- cobicistat tablet, film coated". DailyMed. 27 August 2020. Retrieved 21 September 2020.
- ^ "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Retrieved 21 September 2020.
- ^ "Intelence- etravirine tablet". DailyMed. 9 June 2020. Retrieved 21 September 2020.
- ^ "Cytovene IV- ganciclovir sodium injection, powder, lyophilized, for solution". DailyMed. 19 June 2020. Retrieved 21 September 2020.
- ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3
- ^ "Trogarzo- ibalizumab injection, solution". DailyMed. 8 April 2020. Retrieved 21 September 2020.
- ^ "Prevymis- letermovir tablet, film coated PREVYMIS- letermovir injection, solution". DailyMed. 23 March 2020. Retrieved 21 September 2020.
- ^ "Tamiflu- oseltamivir phosphate capsule TAMIFLU- oseltamivir phosphate powder, for suspension". DailyMed. Retrieved 21 September 2020.
- ^ "Rapivab- peramivir solution". DailyMed. 3 August 2020. Retrieved 21 September 2020.
- ^ "Rebetol, Ribasphere (ribavirin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 28 February 2014. Retrieved 23 February 2014.
- ^ "Edurant- rilpivirine hydrochloride tablet, film coated". DailyMed. 8 June 2020. Retrieved 21 September 2020.
- ^ Berden FA, Kievit W, Baak LC, Bakker CM, Beuers U, Boucher CA, Brouwer JT, Burger DM, van Erpecum KJ, van Hoek B, Hoepelman AI, Honkoop P, Kerbert-Dreteler MJ, de Knegt RJ, Koek GH, van Nieuwkerk CM, van Soest H, Tan AC, Vrolijk JM, Drenth JP (October 2014). "Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era". The Netherlands Journal of Medicine. 72 (8): 388–400. PMID 25387551.
- ^ Gish RG (January 2006). "Treating HCV with ribavirin analogues and ribavirin-like molecules". The Journal of Antimicrobial Chemotherapy. 57 (1): 8–13. doi:10.1093/jac/dki405. PMID 16293677
- ^ "Tenofovir Disoproxil Fumarate". The American Society of Health-System Pharmacists. Archived from the original on 30 November 2016. Retrieved 29 November 2016.
- ^ "Valtrex- valacyclovir hydrochloride tablet, film coated". DailyMed. 10 December 2019. Retrieved 21 September 2020.
- ^ "Valcyte- valganciclovir tablet, film coated VALCYTE- valganciclovir hydrochloride powder, for solution". DailyMed. 9 August 2018. Retrieved 3 September 2022.
- ^ "Relenza- zanamivir powder". DailyMed. 21 June 2018. Retrieved 21 September 2020.
- ^ "Zidovudine". PubChem Public Chemical Database. NCBI. Archived from the original on October 25, 2012. Retrieved April 10, 2011.